Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
About the study
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
- Women must not be pregnant, lactating, or breastfeeding
EXCLUSION CRITERIA
Exclusion Criteria:
- Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
- To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.
Other protocol-defined inclusion/exclusion criteria apply
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Psoriasis
Age (in years)
18+
Phase
PHASE3
Participants Needed
1452
Est. Completion Date
Jul 26, 2026
Treatment Type
INTERVENTIONAL
Sponsor
Bristol-Myers Squibb
ClinicalTrials.gov NCT Identifier
NCT04036435
Study Number
IM011075
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?